Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced Metastatic NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07780578
What this trial is testing

The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line
Fudan University 34
Early research (Phase 1)Active Not RecruitingNCT05704985
What this trial is testing

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Who this might be right for
CancerSolid TumorColorectal Cancer+6 more
DEKA Biosciences 39
Not applicableStudy completedNCT00997230
What this trial is testing

Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m

Who this might be right for
Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca 4,243
Early research (Phase 1)Study completedNCT03468426
What this trial is testing

Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Who this might be right for
Non-squamous, Non-Small-Cell Lung CancerNeoplasms
Boehringer Ingelheim 252
Early research (Phase 1)Looking for participantsNCT06946927
What this trial is testing

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
Jemincare 72
Early research (Phase 1)Study completedNCT01772004
What this trial is testing

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Who this might be right for
Solid Tumors
EMD Serono Research & Development Institute, Inc. 1,756
Testing effectiveness (Phase 2)Looking for participantsNCT07362940
What this trial is testing

A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib

Who this might be right for
Non-Small Cell Lung Cancer
Henan Genuine Biotech Co., Ltd. 110
Testing effectiveness (Phase 2)UnknownNCT04063462
What this trial is testing

Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 60
Early research (Phase 1)Study completedNCT00327288
What this trial is testing

Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients

Who this might be right for
Non-small Cell Lung CancerBreast CancerProstate Cancer
AmpliMed Corporation 34
Large-scale testing (Phase 3)Study completedNCT02454933
What this trial is testing

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

Who this might be right for
Locally Advanced or Metastatic EGFR T790M+ NSCLC
AstraZeneca 29
Testing effectiveness (Phase 2)Study completedNCT00152477
What this trial is testing

Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer

Who this might be right for
CarcinomaNon-Squamous Non-Small-Cell Lung Cancer
UCB Pharma 165
Large-scale testing (Phase 3)Not Yet RecruitingNCT07442565
What this trial is testing

SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

Who this might be right for
Non-Small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd. 506
Large-scale testing (Phase 3)Active Not RecruitingNCT04143607
What this trial is testing

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 337
Testing effectiveness (Phase 2)Active Not RecruitingNCT03485209
What this trial is testing

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Who this might be right for
Colorectal NeoplasmsCarcinoma, Non-Small-Cell LungExocrine Pancreatic Cancer+1 more
Seagen, a wholly owned subsidiary of Pfizer 350
Testing effectiveness (Phase 2)Looking for participantsNCT04665206
What this trial is testing

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Who this might be right for
Solid Tumor, AdultMesotheliomaNSCLC
Vivace Therapeutics, Inc 434
Testing effectiveness (Phase 2)Looking for participantsNCT06682793
What this trial is testing

Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Who this might be right for
Solid Tumor, AdultColorectal CancerNon-Small Cell Lung+14 more
A2 Biotherapeutics Inc. 240
Early research (Phase 1)Study completedNCT03821233
What this trial is testing

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Who this might be right for
HER2-expressing Cancers
Zymeworks BC Inc. 112
Testing effectiveness (Phase 2)Study completedNCT01250119
What this trial is testing

Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 688
Large-scale testing (Phase 3)Active Not RecruitingNCT04603807
What this trial is testing

Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 217
Early research (Phase 1)Study completedNCT02457793
What this trial is testing

The Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
Genentech, Inc. 24
Next Page